The global heart pump device market size was valued at USD 3.45 billion in 2025 and is projected to grow from USD 3.91 billion in 2026 to USD 12.13 billion by 2035, at a CAGR of 13.4% from 2026 to 2035. North America dominated the market, accounting for a revenue share of 53.0% in 2025.
The heart pump device market is an integral component of the broader cardiovascular medical devices industry. Designed to support or replace the function of a failing heart, heart pump devices are predominantly used in patients with end-stage heart failure and those awaiting heart transplants. Technological advancements, the increasing prevalence of cardiovascular diseases (CVDs), and rising geriatric populations are major forces contributing to market expansion.
Globally, millions suffer from heart failure, with the World Health Organization (WHO) estimating cardiovascular diseases as the leading cause of death. Heart pump devices offer a lifeline by either temporarily or permanently supporting the heart's pumping function, particularly when pharmacological treatments are insufficient. The growing acceptance of mechanical circulatory support systems and increased government investments in healthcare infrastructure are also accelerating the adoption of these devices.
The market has witnessed significant evolution, with the introduction of compact, battery-operated, and biocompatible heart pump systems. Companies are continually innovating to make devices more reliable, durable, and cost-effective. In parallel, the awareness among clinicians and patients about mechanical circulatory support has surged, catalyzing adoption across developed and emerging regions.
Artificial intelligence (AI) is revolutionizing the market, such as Total Artificial Hearts (TAHs) and Ventricular Assist Devices (VADs), by enabling them to be more proactive and smarter. It allows devices to directly adjust to a patient's activity and safeguard from life-threatening issues before they happen. Furthermore, artificial intelligence and machine learning algorithms continuously monitor a patient’s vital parameters such as oxygen saturation and physical activity to dynamically regulate blood flow.
Miniaturization of Devices: Manufacturers are developing smaller, portable heart pump systems suitable for implantation or external use without sacrificing efficacy.
Growth in Bridge-to-Transplant (BTT) and Destination Therapy (DT): These applications are driving demand as more patients await transplants or use devices permanently.
Rising Use of Left Ventricular Assist Devices (LVADs): LVADs dominate product demand, particularly in patients with left ventricular heart failure.
Integration of Artificial Intelligence (AI): Smart heart pump are being explored for real-time monitoring and automated function adjustment.
Shift Towards Implantable Devices: Due to better outcomes and mobility for patients, there is increasing preference for implanted solutions over extracorporeal systems.
Robust R&D and Clinical Trials: There is a surge in research efforts aimed at improving biocompatibility, reducing hemolysis, and enhancing device longevity.
Public and Private Investments in Cardiac Healthcare: Numerous countries are investing in cardiovascular health, including funding for advanced heart support systems.
Telemonitoring and Remote Diagnostics: The inclusion of digital health technologies enables post-implant monitoring, reducing hospital readmissions.
Rising Incidence of Heart Failure in Younger Populations: Lifestyle changes and metabolic syndromes are pushing the disease burden to younger demographics.
| Report Coverage | Details |
| Market Size in 2026 | USD 3.91 Billion |
| Market Size by 2035 | USD 12.13 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 13.4% |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Segments Covered | Type, Product, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Abbott; ABIOMED (Johnson & Johnson Services Inc; Getinge ;LivaNova PLC; Berlin Heart; Picard Medical Inc. (SynCardia Systems LLC); Jarvik Heart; BiVACOR Inc.; Leviticus Cardio; Teleflex Incorporated. |
One of the strongest drivers of the heart pump device market is the rising incidence of heart failure, which affects over 26 million people globally. Sedentary lifestyles, dietary imbalances, hypertension, diabetes, and obesity contribute significantly to heart-related disorders. Heart pump devices serve as either short-term support during surgery or long-term aids for chronic heart failure patients.
For instance, in the United States alone, nearly 6.5 million adults suffer from heart failure, and approximately 1 in 9 deaths include heart failure as a contributing cause. With limited donor hearts available, mechanical devices like LVADs or extracorporeal systems become essential. This necessity is further amplified by aging demographics, as cardiovascular disease is more prevalent in older adults. As the need for mechanical circulatory support rises, so does demand for high-performance, minimally invasive heart pump devices.
Despite technological advancement and proven efficacy, the high cost of heart pump devices and associated surgical procedures remains a significant barrier, especially in low- and middle-income countries. A typical LVAD can cost upwards of USD 80,000, excluding hospitalization, follow-up care, and medications. This limits access for a vast segment of patients who either lack insurance coverage or reside in countries with constrained healthcare budgets.
Moreover, maintenance and complications, such as infection or thromboembolism, may result in additional healthcare expenditures. Reimbursement challenges also hinder widespread adoption, particularly for novel or experimental devices. Although cost-containment strategies and government support are improving in some regions, affordability remains a pressing issue, curbing the market’s full potential.
Emerging economies such as India, Brazil, and Southeast Asian nations present a compelling opportunity for market expansion, driven by improving healthcare infrastructure, rising awareness of heart failure management, and growing medical tourism.
Countries like India are investing in cardiac centers and medical device manufacturing, while also witnessing a rising middle-class population willing to spend on premium healthcare services. Strategic collaborations between global device manufacturers and regional hospitals or distributors are helping expand product accessibility.
Furthermore, initiatives by non-profits and government programs to subsidize heart failure treatment combined with the declining cost of older generation devices—can open doors for widespread adoption in these underpenetrated markets.
Why did the implanted heart pump devices segment dominate the global heart pump devices market?
The implanted heart pump devices segment dominated the market with the largest share in 2025. The dominance of the segment can be attributed to the increasing prevalence of heart failure and the advancement of innovative technologies such as miniaturized devices that are easier to implant. In addition, these medical systems feature wireless connectivity and extended battery longevity, enabling patients to resume their professional duties, enjoy greater mobility, and maintain a high standard of daily living outside the hospital.
How did the extracorporeal heart pump devices segment expected to hold the significantly growing global heart pump devices market in the coming years?
The extracorporeal heart pump devices segment is expected to grow at the fastest CAGR over the forecast period. The growth of the segment can be credited to the extensive shortage of donor organs and technological innovations such as miniaturization. Extracorporeal devices are mainly used for temporary mechanical circulatory support. These systems play a critical role in emergency care, intensive care units, and complex or high-risk cardiac interventions.
Why did the Ventricular Assist Devices (VADs) segment dominate the global heart pump devices market?
The Ventricular Assist Devices (VADs) segment dominated the market with the largest share in 2025. The dominance of the segment can be linked to the increasing elderly population and technological innovations in miniaturization. Surgeons increasingly use fewer invasive techniques to implant VADs, which results in smaller incisions, reduced physiological trauma, and smooth patient recovery.
How did the Extracorporeal Membrane Oxygenation (ECMO) segment expected to hold the significantly growing global heart pump devices market in the coming years?
The Extracorporeal Membrane Oxygenation (ECMO) segment is expected to grow at the fastest CAGR during the projected period. The growth of the segment can be driven by the increasing incidence of severe cardiac and respiratory diseases and growing clinical application for various emergencies. Extracorporeal membrane oxygenation (ECMO) serves as a critical life-support modality that temporarily mimics the function of the heart and lungs.
Why did the hospital segment dominate the global heart pump devices market?
The hospital segment dominated the market with the largest share in 2025. The dominance of the segment is owing to the ongoing transition towards minimally invasive procedures and technological innovations such as miniaturized pumps. Emerging economies are actively modernizing their medical facilities. This development enables a growing number of healthcare institutions to establish dedicated cardiac care and surgical centers.
How did the cardiac center segment expected to hold the significantly growing global heart pump devices market in the coming years?
The cardiac center segment is expected to grow at the fastest CAGR during the study period. The growth of the segment is due to the increasing incidence of chronic disease and growing clinical trials. Furthermore, the prevalence of severe heart failure is rising within cardiac facilities. With the progression of the disease, a significant number of patients need mechanical support modalities, including Ventricular Assist Devices (VADs).
Why did the North American region account for the largest share in the global heart pump devices market?
North America dominated the market with the largest share in 2025. The dominance of the region can be attributed to a robust network of established intensive care and cardiac transplant centers along with the favourable reimbursement policies. In addition, major medical corporations give substantial capital to research and development, yielding smaller, more durable, and highly efficient pumps that enhance patient mortality and clinical comfort.
U.S. Global Heart Pump Devices Market Trends
The growth of the market in the country can be driven by technological innovations in miniaturization and the presence of advanced healthcare infrastructure. Also, favourable reimbursement policies and the presence of leading industry manufacturers, such as Abbott and Medtronic, facilitate the rapid adoption of these life-saving technologies.
Why did the Asia-Pacific region become the fastest-growing global heart pump devices market during the forecast period?
Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The growth of the region can be credited to the increasing access to innovative surgical care across emerging economies such as China and India. Furthermore, many patients seeking affordable, world-class cardiac care frequently travel to hubs in India, Thailand, and South Korea. This growth of medical tourists drives higher demand and use of advanced heart pumps across these nations.
China Global Heart Pump Devices Market Trends
The market in the country is growing due to the ongoing healthcare infrastructure expansion and long organ transplant wait times. An increasing number of tertiary care institutions are now equipped with the advanced capabilities required to manage complex, high-risk cardiac procedures, driving market growth further.
February 2025: Medtronic announced the completion of its pilot trial for a new wireless LVAD system in Europe, indicating a breakthrough in reducing driveline infections.
January 2025: Abbott received FDA approval for an upgraded version of its HeartMate 3 with enhanced monitoring capabilities and longer battery life.
October 2024: Abiomed launched the Impella ECP (Expandable Cardiac Pump) in select U.S. hospitals under an Early Access Program, emphasizing its role in high-risk PCI.
August 2024: Berlin Heart reported successful pediatric heart transplant bridge outcomes using the EXCOR Pediatric VAD in multiple European countries.
June 2024: A collaborative study between Cleveland Clinic and University of Tokyo showcased improved survival rates for ECMO-supported patients during the pandemic, strengthening clinical evidence for extracorporeal heart pump devices.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the Operating room equipment market
By Type
By Product
By End Use
By Regional
Heart Pump Device Market
Download Sample
Request Customization
Request Customization
Download Sample